Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec 18;28(154):190128.
doi: 10.1183/16000617.0128-2019. Print 2019 Dec 31.

Pulmonary arterial hypertension registries: past, present and into the future

Jason Weatherald  1   2 , Abílio Reis  3 , Olivier Sitbon  4   5   6 , Marc Humbert  4   5   6
Affiliations
Editorial

Pulmonary arterial hypertension registries: past, present and into the future

Jason Weatherald et al. Eur Respir Rev. .

Abstract

Registries have greatly contributed to knowledge about PAH epidemiology, risk factors, prognosis and treatment. Future registries face unique challenges but may benefit from integration of multiple data sources and capitalising on “Big Data” opportunities. http://bit.ly/2OBpapG

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: J. Weatherald reports grants, personal fees and non-financial support from Janssen Inc. and Actelion, personal fees and non-financial support from Bayer, personal fees from Novartis, and grants from Alberta Lung Association, Canadian Vascular Network, European Respiratory Society and Canadian Thoracic Society, outside the submitted work. Conflict of interest: A. Reis reports grants, personal fees and non-financial support from Janssen Inc. and Actelion, outside the submitted work. Conflict of interest: O. Sitbon reports grants, personal fees and non-financial support from Actelion Pharmaceuticals, Bayer and Merck, grants from GlaxoSmithKline, grants, and personal fees from United Therapeutics and Gossamer Bio, outside the submitted work. Conflict of interest: M. Humbert reports personal fees from Actelion and Merck, and grants and personal fees from Bayer, GSK and United Therapeutics, outside the submitted work.

References

    1. U.S. Food & Drug Administration. Real-World Evidence. www.fda.gov/science-research/science-and-research-special-topics/real-wo... Date last updated: 05 September 2019. Date last accessed: 17 September 2019.
    1. Swinnen K, Quarck R, Godinas L, et al. . Learning from registries in pulmonary arterial hypertension: pitfalls and Recommendations. Eur Respir Rev 2019; 28: 190050. - PMC - PubMed
    1. Galiè N, Channick RN, Frantz RP, et al. . Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 2019; 53: 1801889. doi:10.1183/13993003.01889-2018 - DOI - PMC - PubMed
    1. Hoeper MM, Kramer T, Pan Z, et al. . Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J 2017; 50: 1700740. doi:10.1183/13993003.00740-2017 - DOI - PubMed
    1. Boucly A, Weatherald J, Savale L, et al. . Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J 2017; 50: 1700889. doi:10.1183/13993003.00889-2017 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources